Literature DB >> 11337125

Vaccination of sheep against Fasciola hepatica with homologous fatty acid binding proteins.

V Ramajo1, A Oleaga, P Casanueva, G V Hillyer, A Muro.   

Abstract

The current study was designed to test the immunoprophylactic properties of native (nFh12) and recombinant (rFh15) antigens from Fasciola hepatica in sheep subsequently infected with the fluke. Thirty lambs were divided into six groups according to various patterns of immunisation and times of infection and necropsy. The antigens were emulsified in Freund's adjuvant. Levels of specific anti-nFh12 and anti-rFh15 antibodies rose rapidly by 2 weeks after the first immunisation and were always significantly higher in immunised-infected sheep than in control-infected sheep. On completion of the trial there was no difference in fluke burden between groups vaccinated with either of the antigens and non-immunised controls. However, worm size and faecal egg counts were significantly diminished in the sheep vaccinated with either of the antigens, suggesting an anti-fecundity effect. This is the first report of experimental vaccination of sheep against F. hepatica with purified native and recombinant antigens related to fatty acid binding proteins.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11337125     DOI: 10.1016/s0304-4017(01)00388-0

Source DB:  PubMed          Journal:  Vet Parasitol        ISSN: 0304-4017            Impact factor:   2.738


  15 in total

1.  Preliminary protective capacity study of a Dicrocoelium dendriticum antigenic protein in hamsters.

Authors:  C González-Lanza; M Y Manga-González; B Revilla-Nuín
Journal:  Parasitol Res       Date:  2006-11       Impact factor: 2.289

2.  Vaccination of buffaloes with Fasciola gigantica recombinant glutathione S-transferase and fatty acid binding protein.

Authors:  Niranjan Kumar; Varghese Anju; Nagar Gaurav; Dinesh Chandra; S Samanta; S C Gupta; J Adeppa; O K Raina
Journal:  Parasitol Res       Date:  2011-07-13       Impact factor: 2.289

3.  Partial immunity to Fasciola hepatica in mice after vaccination with FhSAP2 delivered as recombinant protein or DNA construct.

Authors:  Ana M Espino; Adelaida Morales; Bonnibel Delgado; Francheska M Rivera; Olgary Figueroa; Erick Suárez
Journal:  Ethn Dis       Date:  2010       Impact factor: 1.847

4.  Evaluation of a 14.5 kDa-Fasciola gigantica fatty acid binding protein as a diagnostic antigen for human fascioliasis.

Authors:  Gamal Allam; Ibrahim R Bauomy; Zeinab M Hemyeda; Thabet F Sakran
Journal:  Parasitol Res       Date:  2011-11-24       Impact factor: 2.289

5.  Fasciola hepatica and Schistosoma mansoni: identification of common proteins by comparative proteomic analysis.

Authors:  Nawal M Boukli; Bonnibel Delgado; Martha Ricaurte; Ana M Espino
Journal:  J Parasitol       Date:  2011-03-11       Impact factor: 1.276

6.  Vaccination of buffaloes with Fasciola gigantica recombinant fatty acid binding protein.

Authors:  P Azhahia Nambi; S C Yadav; O K Raina; D Sriveny; Mohini Saini
Journal:  Parasitol Res       Date:  2005-06-29       Impact factor: 2.289

7.  Significance of a common 65 kDa antigen in the experimental fasciolosis and toxoplasmosis.

Authors:  Raafat Mohamed Shaapan; Nagwa Ibrahim Toaleb; Eman Hussein Abdel-Rahman
Journal:  J Parasit Dis       Date:  2013-11-20

8.  Milk As a New Diagnostic Tool for Rapid Detection of Fascioliasis in Dairy Goats Using Excretory/Secretory Antigen.

Authors:  Mena F Saad; Marwa M Attia
Journal:  Acta Parasitol       Date:  2020-09-29       Impact factor: 1.440

9.  Direct interaction between EgFABP1, a fatty acid binding protein from Echinococcus granulosus, and phospholipid membranes.

Authors:  Jorge L Porfido; Gabriela Alvite; Valeria Silva; Malcolm W Kennedy; Adriana Esteves; Betina Corsico
Journal:  PLoS Negl Trop Dis       Date:  2012-11-15

10.  Quantitation of cytokine mRNA by real-time RT-PCR during a vaccination trial in a rabbit model of fascioliasis.

Authors:  Ana M Espino; Francheska Rivera
Journal:  Vet Parasitol       Date:  2009-12-22       Impact factor: 2.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.